108,811 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 108,811 shares of the company’s stock, valued at approximately $4,943,000. Janux Therapeutics accounts for 2.6% of Ally Bridge Group NY LLC’s holdings, making the stock its 20th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD purchased a new position in shares of Janux Therapeutics during the 1st quarter valued at approximately $739,000. Virtu Financial LLC acquired a new position in Janux Therapeutics during the first quarter worth $609,000. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Janux Therapeutics in the second quarter valued at about $1,676,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JANX shares. Scotiabank decreased their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. Wedbush reissued an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $67.70.

Insider Buying and Selling

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06. Following the sale, the insider now owns 7,000 shares in the company, valued at $296,310. This represents a 23.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the completion of the sale, the chief executive officer now directly owns 307,054 shares in the company, valued at $14,219,670.74. This represents a 7.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 445,610 shares of company stock valued at $20,578,666 in the last ninety days. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Trading Down 3.4 %

Shares of NASDAQ JANX opened at $46.39 on Thursday. The stock has a fifty day simple moving average of $50.02 and a 200-day simple moving average of $45.82. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $65.60. The stock has a market capitalization of $2.43 billion, a PE ratio of -39.65 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm’s quarterly revenue was down 82.6% on a year-over-year basis. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.